These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26018216)

  • 1. Disrupted vasculature and blood-brain barrier in Huntington disease.
    Waldvogel HJ; Dragunow M; Faull RL
    Ann Neurol; 2015 Aug; 78(2):158-9. PubMed ID: 26018216
    [No Abstract]   [Full Text] [Related]  

  • 2. Aberrant astrocytes impair vascular reactivity in Huntington disease.
    Hsiao HY; Chen YC; Huang CH; Chen CC; Hsu YH; Chen HM; Chiu FL; Kuo HC; Chang C; Chern Y
    Ann Neurol; 2015 Aug; 78(2):178-92. PubMed ID: 25914140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology.
    Drouin-Ouellet J; Sawiak SJ; Cisbani G; Lagacé M; Kuan WL; Saint-Pierre M; Dury RJ; Alata W; St-Amour I; Mason SL; Calon F; Lacroix S; Gowland PA; Francis ST; Barker RA; Cicchetti F
    Ann Neurol; 2015 Aug; 78(2):160-77. PubMed ID: 25866151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegenerative disease: neuron protection agency.
    Orr HT
    Nature; 2004 Oct; 431(7010):747-8. PubMed ID: 15483586
    [No Abstract]   [Full Text] [Related]  

  • 5. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
    Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
    BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific.
    Jansen AH; van Hal M; Op den Kelder IC; Meier RT; de Ruiter AA; Schut MH; Smith DL; Grit C; Brouwer N; Kamphuis W; Boddeke HW; den Dunnen WF; van Roon WM; Bates GP; Hol EM; Reits EA
    Glia; 2017 Jan; 65(1):50-61. PubMed ID: 27615381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the duration of hyperlipidemia on cerebral lipids, vessels and neurons in rats.
    Yang W; Shi H; Zhang J; Shen Z; Zhou G; Hu M
    Lipids Health Dis; 2017 Jan; 16(1):26. PubMed ID: 28143622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astrocytic TYMP and VEGFA drive blood-brain barrier opening in inflammatory central nervous system lesions.
    Chapouly C; Tadesse Argaw A; Horng S; Castro K; Zhang J; Asp L; Loo H; Laitman BM; Mariani JN; Straus Farber R; Zaslavsky E; Nudelman G; Raine CS; John GR
    Brain; 2015 Jun; 138(Pt 6):1548-67. PubMed ID: 25805644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The localization and interactions of huntingtin.
    Jones AL
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1021-7. PubMed ID: 10434301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Huntingtin's critical cleavage.
    Fryer JD; Zoghbi HY
    Nat Neurosci; 2006 Sep; 9(9):1088-9. PubMed ID: 16936769
    [No Abstract]   [Full Text] [Related]  

  • 11. Astrocyte-Derived Pentraxin 3 Supports Blood-Brain Barrier Integrity Under Acute Phase of Stroke.
    Shindo A; Maki T; Mandeville ET; Liang AC; Egawa N; Itoh K; Itoh N; Borlongan M; Holder JC; Chuang TT; McNeish JD; Tomimoto H; Lok J; Lo EH; Arai K
    Stroke; 2016 Apr; 47(4):1094-100. PubMed ID: 26965847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
    Arrasate M; Mitra S; Schweitzer ES; Segal MR; Finkbeiner S
    Nature; 2004 Oct; 431(7010):805-10. PubMed ID: 15483602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease.
    Schwab C; Arai T; Hasegawa M; Yu S; McGeer PL
    J Neuropathol Exp Neurol; 2008 Dec; 67(12):1159-65. PubMed ID: 19018245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
    Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
    J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington's disease: genetics lends a hand.
    Palfi S; Jarraya B
    Nature; 2008 Jun; 453(7197):863-4. PubMed ID: 18488017
    [No Abstract]   [Full Text] [Related]  

  • 16. Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease.
    Meunier C; Merienne N; Jollé C; Déglon N; Pellerin L
    Glia; 2016 Nov; 64(11):1841-56. PubMed ID: 27442486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RAGE receptor and its ligands are highly expressed in astrocytes in a grade-dependant manner in the striatum and subependymal layer in Huntington's disease.
    Kim J; Waldvogel HJ; Faull RL; Curtis MA; Nicholson LF
    J Neurochem; 2015 Sep; 134(5):927-42. PubMed ID: 26011179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertonic saline alleviates experimentally induced cerebral oedema through suppression of vascular endothelial growth factor and its receptor VEGFR2 expression in astrocytes.
    Huang L; Cao W; Deng Y; Zhu G; Han Y; Zeng H
    BMC Neurosci; 2016 Oct; 17(1):64. PubMed ID: 27733124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin protein expression and blood-spinal cord barrier dysfunction in huntington disease.
    Sciacca G; Cicchetti F
    Ann Neurol; 2017 Dec; 82(6):981-994. PubMed ID: 29171910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegenerative disease: cut to the chase.
    Ellerby LM; Orr HT
    Nature; 2006 Aug; 442(7103):641-2. PubMed ID: 16900190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.